In adults, the most common condition was optic neuritis at 61%. In the children, ADEM was the most prevalent condition at 38% followed by optic neuritis at 25%. The researchers then investigated whether there were specific binding patterns between MOG antibody and MOG in different demyelinating conditions that could help with diagnosis in the future.Īll 287 people were positive for MOG antibody. They developed a live cell-based test to detect MOG antibody – meaning the cells from these people are biologically active. Published in Acta Neuropathologica Communications, MS Research Australia-supported researcher Associate Professor Fabienne Brilot-Turville and her team have characterised MOG antibody in 139 children and 148 adults with different demyelinating conditions. Understanding the features of MOG antibody in different demyelinating conditions will improve diagnosis and management of these conditions. While the clinical spectrum of MOG antibody disorders has been explored, its response in different demyelinating disorders hasn’t been looked at much. All of these conditions can present with symptoms similar to MS. The presence of MOG antibodies has been associated with many demyelinating conditions in children and adults including optic neuritis, acute disseminated encephomyelitis (ADEM) and transverse myelitis. In many demyelinating conditions, it is MOG antibodies that lead to damage of the myelin. Normally, antibodies are produced by the body to fight off infections, but sometimes they can mistakenly attack tissues in the body and in MS the antibodies are directed against the myelin. Damage in MS is due to the attack of antibodies. Myelin oligodendrocyte glycoprotein (MOG) is an important protein that makes up myelin, the insulating layer of the nerve fibres in the brain and spinal cord that is damaged in MS. What is myelin oligodendrocyte glycoprotein (MOG) and MOG antibody? This new test is currently undergoing approval for use in the clinic to help with diagnosis and disease course prediction in different demyelinating conditions.In exciting findings, the researchers developed a new test that showed that MOG antibody levels are higher in more severe conditions, and its binding patterns are different depending on the condition.A team of Australasian researchers looked at MOG antibody in demyelinating conditions to determine its features in different conditions.Myelin oligodendrocyte glycoprotein (MOG) antibody is associated with many demyelinating conditions, but it has not be characterised in-depth.The International MS Genetics Consortium.
![mog antibody testing mog antibody testing](https://th2cells.com/wp-content/uploads/2020/07/103120957_2629898784003757_1172033395519149055_n.jpg)
MOG ANTIBODY TESTING TRIAL
Vitamin D MS Prevention Trial – PrevANZ.